Proteomic signatures for fibrosis in MASLD: a biopsy-proven dual-cohort study
A biomarker model including ACE2, HGF and IGFBP7 shows promise in distinguishing between low-stage and significant fibrosis.
Authors
- Stergios Kechagias (ORCID: https://orcid.org/0000-0001-7614-739X)
- Julia Blomdahl (ORCID: https://orcid.org/0000-0002-6364-8758)
- Fredrik Rorsman (ORCID: https://orcid.org/0000-0003-4023-9617)
- Håkan Åhlström (ORCID: https://orcid.org/0000-0002-8701-969X)
- Niclas Eriksson (ORCID: https://orcid.org/0000-0002-2152-4343)
- Ulf Risérus (ORCID: https://orcid.org/0000-0002-8620-4586)
- Michael Fridén (ORCID: https://orcid.org/0000-0002-6545-4439)
- Mattias Ekstedt (ORCID: https://orcid.org/0000-0002-5590-8601)
- Patrik Nasr (ORCID: https://orcid.org/0000-0002-2928-4188)
- Katja Gabrysch (ORCID: https://orcid.org/0009-0003-4234-8814)
- Johan Vessby (ORCID: https://orcid.org/0000-0003-1832-6386)
- Paul Hockings (ORCID: https://orcid.org/0000-0002-7154-9047)
- Mikael Åberg (ORCID: https://orcid.org/0000-0002-7858-8233)
- Johannes Hulthe
Institutions
- Linköping University (SE)
- Uppsala University (SE)
- Science for Life Laboratory (SE)
- Antaros Medical (Sweden) (SE)
- Wallenberg Wood Science Center (SE)
Publication Details
- Journal
- Scandinavian Journal of Gastroenterology
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1080/00365521.2025.2490996
- Citations
- 2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- Boehringer Ingelheim